Basic information Safety Related Supplier

ChemicalBook Product Catalog Naroparcil

1/1

Naroparcil NEW

$130.00 1mg

$317.00 5mg

$445.00 10mg

Min. Order
Purity99.99%
Cas No120819-70-7
Supply Ability10g
Update time2026-04-12

TargetMol Chemicals Inc.

TargetMol Chemicals Inc.

VIP6Y

United States

United States

show more

Enterprise Verified

Business Bank account Basic Contact Infomation Business Address Trade Company

Chemical Properties

Product Name	Naroparcil
CAS No	120819-70-7
EC-No
Min. Order
Purity	99.99%
Supply Ability	10g
Release date	2026/04/12

Product Introduction

Bioactivity

Name	Naroparcil
Description	Naroparcil, an orally available thioglycoside analog of 4-methylumbelliferyl β-D-xyloside, showed antithrombotic effects in the Wessler sludge model of venous thrombosis (jugular vein).Naroparcil enhanced the formation of the thrombin/heparin cofactor II complex, induced dermatophyte sulfate-like substances in plasma from treated rabbits appearance, but reduced the formation of thrombin/antithrombin III complexes in plasma incubated with (125I)-human alpha-thrombin.
In vivo	Naroparcil attenuated thrombus development in a Wessler stasis model of venous thrombosis (jugular vein) employing bovine factor Xa as a thrombogenic stimulus giving ED50 values of 21.9 mg/kg and 36.0 mg/kg after respectively i.v. and p.o.. Venous antithrombotic activity was maximal 2-3 h after i.v. administration and 4-8 h after oral administration. Four hours after the oral administration of maximal antithrombotic (Wessler model, factor Xa) doses (100 and 400 mg/kg), naroparcil had no significant effect on bleeding time. In platelet-poor plasma obtained from animals treated 4 h previously with various doses (25 to 400 mg/kg) of naroparcil, there was no detectable anti-factor Xa nor antithrombin activity. Similarly, naroparcil had no effect on APTT nor on thrombin time. A sensitized thrombin time (to about 35 s) was modestly but significantly increased following oral administration of the compound at 400 mg/kg. However, thrombin generation by the intrinsic pathway was reduced in a dose-related manner, with maximal reduction being 65% at 400 mg/kg. The same dose of naroparcil enhanced the formation of thrombin/heparin cofactor II complexes at the expense of thrombin/antithrombin III complexes in plasma incubated with (125I)-human alpha-thrombin and induced the appearance of dermatan sulfate-like material in the plasma of treated rabbits, as measured by a heparin cofactor II-mediated thrombin inhibition assay.[1]
Storage	02 \| Shipping with blue ice/Shipping at ambient temperature.
Solubility Information	DMSO : 50 mg/mL (129.04 mM), Sonication is recommended.
Keywords	Thrombin
Inhibitors Related	Dabigatran Etexilate Mesylate \| (S)-(+)-Ibuprofen \| Edoxaban \| AEBSF hydrochloride \| Heparin sodium salt \| Ozagrel \| Dabigatran etexilate \| Apixaban \| 2-Methoxyphenothiazine \| Coumarin \| p-Hydroxycinnamic acid \| Fondaparinux sodium
Related Compound Libraries	Bioactive Compound Library \| Protease Inhibitor Library \| Anti-Cardiovascular Disease Compound Library \| Orally Active Compound Library \| Bioactive Compounds Library Max \| Human Metabolite Library

show more

Company Profile Introduction

You may like

Recommended supplier

Send Inquriy